BiotechTube

Placebo + Adalimumab

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hidradenitis Suppurativa (HS)

Conditions

Hidradenitis Suppurativa (HS)

Trial Timeline

Jul 18, 2016 → Oct 16, 2019

NCT ID
NCT02808975

About Placebo + Adalimumab

Placebo + Adalimumab is a approved stage product being developed by AbbVie for Hidradenitis Suppurativa (HS). The current trial status is completed. This product is registered under clinical trial identifier NCT02808975. Target conditions include Hidradenitis Suppurativa (HS).

What happened to similar drugs?

0 of 20 similar drugs in Hidradenitis Suppurativa (HS) were approved

Approved (0) Terminated (0) Active (20)
🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3
🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3
🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
🔄Lutikizumab + PlaceboAbbViePhase 3
🔄Upadacitinib + PlaceboAbbViePhase 3
🔄adalimumab + placeboAbbViePhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02808975ApprovedCompleted

Competing Products

20 competing products in Hidradenitis Suppurativa (HS)

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab (M1095) + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Eltrekibart + PlaceboEli LillyPhase 2
39
Placebo + LY3041658Eli LillyPhase 2
35
Lutikizumab + PlaceboAbbViePhase 3
47
AdalimumabAbbViePre-clinical
26
Upadacitinib + PlaceboAbbViePhase 3
47
adalimumab + placeboAbbViePhase 3
40
LutikizumabAbbViePhase 2
42
adalimumabAbbViePhase 3
40
Lutikizumab + PlaceboAbbViePhase 2
39
Risankizumab + Placebo for risankizumabAbbViePhase 2
35
adalimumabAbbViePhase 3
40
adalimumab + placeboAbbViePhase 3
40
Upadacitinib + PlaceboAbbViePhase 2
35
MEDI8968 + SalineAstraZenecaPhase 2
27
AnifrolumabAstraZenecaPhase 2
39